Kawasaki Vs MIS-C

← Back to Index (Infectious Diseases)

Introduction

The emergence of Multisystem Inflammatory Syndrome in Children (MIS-C) during the COVID-19 pandemic presented a significant diagnostic challenge for pediatricians worldwide due to its striking phenotypic resemblance to Kawasaki Disease (KD). Both conditions are characterized by persistent fever, systemic hyperinflammation, and mucocutaneous manifestations. However, as the understanding of MIS-C has evolved, distinct epidemiological, clinical, and laboratory patterns have emerged that allow clinicians to differentiate between these two entities. Distinguishing them is critical, as the management strategiesβ€”particularly regarding the use of corticosteroids and anticoagulationβ€”and the prognosis, especially regarding myocardial function and coronary artery outcomes, differ significantly.

This comparative analysis delineates the key differences between Kawasaki Disease and MIS-C, focusing on epidemiology, clinical presentation, organ system involvement, and laboratory profiles.

Epidemiological Distinctions

Age Distribution

Racial and Ethnic Predisposition

Clinical Divergence

Fever and Onset

Gastrointestinal Involvement

Shock and Hemodynamics

Mucocutaneous Manifestations

The classic criteria for KD (CRASH and Burn: Conjunctivitis, Rash, Adenopathy, Strawberry tongue, Hand/foot changes) are present in MIS-C but often in an incomplete or atypical fashion.

Cardiovascular Pathophysiology

Myocardial Dysfunction vs. Coronary Arteritis The pattern of cardiac involvement provides a crucial distinction.

Laboratory Profiles

**Hematology:

The Platelet Paradox** The complete blood count offers one of the most reliable differentiating features.

Inflammatory and Coagulation Markers

While both conditions are hyperinflammatory states with elevated CRP and ESR, the magnitude and pattern differ.

Cardiac Biomarkers

Viral Serology

Comparative Table: Kawasaki Disease vs. MIS-C

Feature Kawasaki Disease (KD) Multisystem Inflammatory Syndrome in Children (MIS-C)
Epidemiology
Age of Onset Infants and young children (< 5 years). Median ~2 years. Older children and adolescents (6–12 years). Median ~9 years.
Incidence Higher in East Asian populations (Japan, Korea). Higher in African, Afro-Caribbean, and Hispanic populations.
Etiology Unknown trigger; likely ubiquitous agent. Post-infectious immune dysregulation following SARS-CoV-2.
Clinical Features
Fever Prolonged, usually > 5 days. Prolonged, > 38.0Β°C for β‰₯ 24 hours (often 3-5 days).
Shock / Hypotension Rare (< 5% cases). Common (50–80% cases). Vasopressor support often needed.
Gastrointestinal Mild (vomiting/diarrhea) less common. Prominent (80-90%). Severe pain, mimicking appendicitis.
Mucocutaneous Classic: Conjunctivitis, strawberry tongue, rash, edema, desquamation. Present but often variable/incomplete.
Respiratory Mild or absent. Respiratory distress, cough (though less common than in acute COVID).
CNS Symptoms Irritability (aseptic meningitis). Headache, lethargy, encephalopathy, meningismus common.
Cardiac Findings
Pathology Coronary artery vasculitis. Acute myocarditis; Cytokine-induced dysfunction.
Ventricular Function Usually preserved (Normal LVEF). Moderate to severe dysfunction (Reduced LVEF) common.
Coronary Arteries Aneurysms are the primary complication (25% untreated). Dilation usually mild/transient; giant aneurysms rare.
Laboratory Features
Platelets Thrombocytosis (High) in subacute phase. Thrombocytopenia (Low) is characteristic (<150,000/ΞΌL).
Lymphocytes Normal or mild decrease. Profound Lymphopenia (Absolute count <1000 cells/ΞΌL).
Inflammatory Markers Elevated CRP and ESR. Elevated CRP, ESR, Procalcitonin.
Ferritin Moderately elevated. Markedly elevated (>500–1000 ng/mL); macrophage activation picture.
D-Dimer Mild elevation. Significantly elevated; coagulopathy common.
Cardiac Biomarkers Troponin/BNP mild elevation. Troponin and BNP/NT-proBNP markedly elevated.
Sodium Hyponatremia may occur. Hyponatremia common (<135 mEq/L).
SARS-CoV-2 Serology Typically Negative (unless coincidental). Positive (IgG/IgM) indicating past infection.
Management
Standard Therapy IVIG (2 g/kg) + Aspirin. IVIG (2 g/kg) + Steroids (Methylprednisolone) + Low-dose Aspirin.
Refractory Cases Steroids, Infliximab, Cyclosporine. Pulse Steroids, Anakinra, Tocilizumab, Infliximab.
Anticoagulation Aspirin (Antiplatelet). Aspirin +/- Enoxaparin (if thrombosis risk/severe LV dysfunction).